ArticleDiscover oncology2025
Bioinformatics analysis of macrophage-associated genes reveals prognostic signatures and immune landscape in gastric cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Gastric cancer (GC) remains one of the leading causes of cancer-related mortality worldwide. The interaction between macrophages and the tumor immune microenvironment (TME) plays a critical role in disease progression and patient prognosis. In this study, we conducted a comprehensive bioinformatics analysis to identify macrophage-associated prognostic genes and construct a predictive risk model in GC. Using transcriptome data from TCGA (n = 350 tumors, 31 controls) and GEO datasets (GSE84437, n = 483; GSE183904), we applied differential expression analysis (DESeq2), weighted gene co-expression network analysis (WGCNA), single-cell RNA sequencing (Seurat), and Cox-LASSO regression to screen for key prognostic markers. Three genes-GPX3, SERPINE1, and SPARC-were identified and used to build a risk score model. Patients were stratified into high- and low-risk groups. Kaplan-Meier analysis showed significantly shorter survival in the high-risk group (HR = 2.35, p < 0.001). The model achieved strong predictive performance with area under the curve (AUC) values of 0.73, 0.70, and 0.68 at 1, 3, and 5 years, respectively. Immune infiltration analysis using CIBERSORT revealed that GPX3 and SPARC were positively correlated with plasma cells and negatively with M0 macrophages. A nomogram incorporating risk score, age, and N/M stage further improved prognostic accuracy. Drug sensitivity analysis (pRRophetic) identified 27 compounds with differential predicted IC50 values between risk groups.Our study demonstrates that macrophage-associated gene signatures are robust predictors of GC prognosis. These findings provide novel insights into immune regulation and potential therapeutic targets in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.